<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36807703</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2151-4658</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Arthritis care &amp; research</Title><ISOAbbreviation>Arthritis Care Res (Hoboken)</ISOAbbreviation></Journal><ArticleTitle>Role of Platelet-Bound C4d (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus.</ArticleTitle><Pagination><StartPage>2088</StartPage><EndPage>2095</EndPage><MedlinePgn>2088-2095</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acr.25107</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Platelet-bound complement activation product C4d (PC4d) levels correlate with history of thrombosis in patients with systemic lupus erythematosus (SLE). The present study evaluated whether PC4d levels could assess risk of future thrombosis events.</AbstractText><AbstractText Label="METHODS">PC4d level was measured by flow cytometry. Thromboses were confirmed by electronic medical record data review.</AbstractText><AbstractText Label="RESULTS">The study included 418 patients. Nineteen events (13 arterial and 6 venous) occurred in 15 subjects in the 3&#x2009;years post-PC4d level measurement. PC4d levels above the optimum cutoff of 13 mean fluorescence intensity (MFI) predicted future arterial thrombosis with a hazard ratio of 4.34 (95% confidence interval [95% CI] 1.03-18.3) (P&#xa0;=&#xa0;0.046) and a diagnostic odds ratio (OR) of 4.30 (95% CI 1.19-15.54). Negative predictive value of PC4d level of &#x2264;13 MFI for arterial thrombosis was 99% (95% CI 97-100%). Although a PC4d level of &gt;13 MFI did not reach statistical significance for prediction of total thrombosis (arterial and venous) (diagnostics OR 2.50 [95% CI 0.88-7.06]; P&#xa0;=&#xa0;0.08), it was associated with all thrombosis (n&#xa0;=&#xa0;70 historic and future arterial and venous events in the 5&#x2009;years pre- to 3&#x2009;years post-PC4d level measurement) with an OR of 2.45 (95% CI 1.37-4.32; P&#xa0;=&#xa0;0.0016). In addition, the negative predictive value of PC4d level of &#x2264;13 MFI for all future thrombosis events was 97% (95% CI 95-99%).</AbstractText><AbstractText Label="CONCLUSIONS">A PC4d level of &gt;13 MFI predicted future arterial thrombosis and was associated with all thrombosis. Patients with SLE presenting with a PC4d level of &#x2264;13 MFI had high probability of not experiencing arterial or any thrombosis in the 3&#x2009;years afterwards. Taken together, these findings indicate that PC4d levels may help predict the risk of future thrombosis events in SLE.</AbstractText><CopyrightInformation>&#xa9; 2023 American College of Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gartshteyn</LastName><ForeName>Yevgeniya</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-5547-4658</Identifier><AffiliationInfo><Affiliation>Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conklin</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Exagen Inc., Vista, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>Michelle A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-1441-5373</Identifier><AffiliationInfo><Affiliation>Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kyttaris</LastName><ForeName>Vasileios C</ForeName><Initials>VC</Initials><Identifier Source="ORCID">0000-0001-7652-3826</Identifier><AffiliationInfo><Affiliation>Beth Israel Deaconess Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Daniel W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-5003-3503</Identifier><AffiliationInfo><Affiliation>Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kammesheidt</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Exagen Inc., Vista, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Askanase</LastName><ForeName>Anca D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0003-4597-5023</Identifier><AffiliationInfo><Affiliation>Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Roberta Vezza</ForeName><Initials>RV</Initials><Identifier Source="ORCID">0000-0001-8827-8637</Identifier><AffiliationInfo><Affiliation>Exagen Inc., Vista, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arthritis Care Res (Hoboken)</MedlineTA><NlmUniqueID>101518086</NlmUniqueID><ISSNLinking>2151-464X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>26</Day><Hour>13</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>12</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36807703</ArticleId><ArticleId IdType="doi">10.1002/acr.25107</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Lu X, Wang YH, Zhang J, et al. Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: a systematic review and meta-analysis. Int Immunopharmacol 2021;94:107466.</Citation></Reference><Reference><Citation>Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002;29:2531-6.</Citation></Reference><Reference><Citation>Ballocca F, D'Ascenzo F, Moretti C, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol 2015;22:1435-41.</Citation></Reference><Reference><Citation>Unlu O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol 2016;3:75-84.</Citation></Reference><Reference><Citation>Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-32.</Citation></Reference><Reference><Citation>Galli M, Luciani D, Bertolini G, et al. Anti-&#x3b2;2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717-23.</Citation></Reference><Reference><Citation>Demir S, Li J, Magder LS, et al. Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus. Rheumatology (Oxford) 2021;60:3770-7.</Citation></Reference><Reference><Citation>Petri MA, Conklin J, O'Malley T, et al. Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE. Lupus Sci Med 2019;6:e000318.</Citation></Reference><Reference><Citation>Svenungsson E, Gustafsson JT, Grosso G, et al. Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus. Rheumatology (Oxford) 2020;59:3264-74.</Citation></Reference><Reference><Citation>Gartshteyn Y, Mor A, Shimbo D, et al. Platelet bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in systemic lupus erythematosus. Clin Immunol 2021;228:108755.</Citation></Reference><Reference><Citation>Kao AH, McBurney CA, Sattar A, et al. Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus. Transl Stroke Res 2014;5:510-8.</Citation></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.</Citation></Reference><Reference><Citation>Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.</Citation></Reference><Reference><Citation>Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.</Citation></Reference><Reference><Citation>Gladman D, Ibanez D, Urowitz M. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29:288-91.</Citation></Reference><Reference><Citation>Sciascia S, Bloch R, Malley TO, et al. Antiphospholipid antibodies are persistently positive at high titers. Additive value of platelet-bound C4d. Front Immunol 2022;13:949919.</Citation></Reference><Reference><Citation>Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77.</Citation></Reference><Reference><Citation>Urowitz MB, Gladman DD, Farewell V, et al. Accrual of atherosclerotic vascular events in a multicenter inception systemic lupus erythematosus cohort. Arthritis Rheumatol 2020;72:1734-40.</Citation></Reference><Reference><Citation>Urowitz MB, Su J, Gladman DD. Atherosclerotic vascular events in systemic lupus erythematosus: an evolving story. J Rheumatol 2020;47:66-71.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>